1.Effect of Epidural Autologous Blood Patch on the Prevention of Post-dural Puncture Headche after Spinal Anesthesia.
Keon Sang LEE ; Yoon Soo KIM ; Jeong Ae LIM ; Po Soon KANG ; Ye Chul LEE
Korean Journal of Anesthesiology 1998;35(5):933-938
Background: Post-dural puncture headache (PDPH) is one of the well-known complication of spinal anesthesia. Epidural blood patch is the treatment of choice for PDPH but is rarely used for the prevention of PDPH after spinal anesthesia. The purpose of this study is to observe the effectiveness of epidural blood patch for prevention of PDPH and to evaluate the complications after epidural blood injection. Methods: Three hundred patients (ASA I or II) receiving spinal anesthesia were studied. They were randomly devided into two groups. Patients in Group I, the control group, were maintained in a supine position for 24 hour after spinal anesthesia. Patients in Group II, the study group, received 3 ml of autologous blood in the epidural space after spinal anesthesia. PDPH was evaluated for 5 days. The incidence, location, onset, and duration of headache in the patients presenting with PDPH were measured for 5 days, and the complications following epidural blood patch in Group II were observed for 2 weeks. Results: The incidence of PDPH in group I was 11%, but 0% in group II. There were no specific complications following epidural blood patch in Group II. Conclusions: This study suggest that the 3 ml epidural autologous blood patch is an useful method for the prevention of PDPH in patients with spinal anesthesia.
Anesthesia, Spinal*
;
Blood Patch, Epidural
;
Epidural Space
;
Headache
;
Humans
;
Incidence
;
Post-Dural Puncture Headache
;
Punctures*
;
Supine Position
2.A Korean boy with atypical X-linked adrenoleukodystrophy confirmed by an unpublished mutation of ABCD1.
Hye Jeong JWA ; Keon Su LEE ; Gu Hwan KIM ; Han Wook YOO ; Han Hyuk LIM
Korean Journal of Pediatrics 2014;57(9):416-419
X-linked adrenoleukodystrophy (X-ALD) is a rare peroxisomal disorder, that is rapidly progressive, neurodegenerative, and recessive, and characteristically primary affects the central nervous system white matter and the adrenal cortex. X-ALD is diagnosed basaed on clinical, radiological, and serological parameters, including elevated plasma levels of very long chain fatty acids (VLCFA), such as C24:0 and C26:0, and high C24:0/C22:0 and C26:0/C22:0 ratios. These tests are complemented with genetic analyses. A 7.5-year-old boy was admitted to Department of Pediatrics, Chungnam National University Hospital with progressive weakness of the bilateral lower extremities. Brain magnetic resonance imaging confirmed clinically suspected ALD. A low dose adrenocorticotropic hormone stimulation test revealed parital adrenal insufficiency. His fasting plasma levels of VLCFA showed that his C24:0/C22:0 and C26:0/C22:0 ratios were significantly elevated to 1.609 (normal, 0-1.390) and 0.075 (normal, 0-0.023), respectively. Genomic DNA was extracted from peripheral whole blood samples collected from the patient and his family. All exons of ABCD1 gene were amplified by polymerase chain reaction (PCR) using specific primers. Amplified PCR products were sequenced using the same primer pairs according to the manufacturer's instructions. We identified a missense mutation (p.Arg163Leu) in the ABCD1 gene of the proband caused by the nucleotide change 488G>T in exon 1. His asymptomatic mother carried the same mutation. We have reported an unpublished mutation in the ABCD1 gene in a patient with X-ALD, who showed increased ratio of C24:0/C22:0 and C26:0/C22:0, despite a normal VLCFA concentrations.
Adrenal Cortex
;
Adrenal Insufficiency
;
Adrenocorticotropic Hormone
;
Adrenoleukodystrophy*
;
Brain
;
Central Nervous System
;
Chungcheongnam-do
;
Complement System Proteins
;
DNA
;
Exons
;
Fasting
;
Fatty Acids
;
Humans
;
Lower Extremity
;
Magnetic Resonance Imaging
;
Male
;
Mothers
;
Mutation, Missense
;
Pediatrics
;
Peroxisomal Disorders
;
Plasma
;
Polymerase Chain Reaction
3.Evaluation of the Collection Efficiency of the Granulocyte in Leukapheresis Using 10% Pentastarch.
Jong Baeck LIM ; Mun Jeong KIM ; Keon Soo YI ; Seung Moo LEE ; Hyun Ok KIM
Korean Journal of Clinical Pathology 1999;19(1):125-130
BACKGROUND: To collect high concentration of granulocytes for transfusion to neutropenic cancer patients with infections, we investigated the effect of G-CSF or dexamethasone as granulocyte mobilizers and 10% pentastarch (PS) as the sedimentation agent in granulocyte collection by leukapheresis. Subsequently, the therapeutic effect of the granulocyte transfusions was assessed. METHODS: Forty five leukapheresis were performed with CS-3000Plus (Baxter, Deerfield, IL, USA) using 10% pentastarch. The donors were classified into three groups according to their premedication drugs and the interface detector offset; group 1 used dexamethasone with offset 15 (n=16), group 2 used dexamethasone with offset 33 (n=16), and group 3 used G-CSF with offset 33 (n=10). We compared total collected granulocyte counts and granulocyte collection efficiency (GCE). RESULTS: The mean counts of total granulocytes collected and GCE were as follows; 0.9 0.5 x 1010 and 31.6 14.3% in group 1, 1.3 0.6 x 1010 and 39.0 14.2% in group 2, and 1.6 0.9 x 1010 and 63.9 32.2% in group 3, respectively. The counts of granulocytes collected in group 3 was significantly higher than that in group 1 (P<0.05). The GCE of group 3 was significantly higher than that of group 1 and group 2 (P<0.05). Sixteen granulocyte transfusions were performed to 11 patients. We observed successful therapeutic effects in 10 out of 16 transfusions (63%). CONCLUSIONS: G-CSF indicates greater potency than dexamethasone although its high cost is limitation of routine use as mobilizing agents and PS was an excellent red cell sedimenting agent in granulocyte collection. Large volume granulocyte transfusions allow high therapeutic effects in neutropenic patients with marrows of sufficient regenerating capacity.
Bone Marrow
;
Dexamethasone
;
Granulocyte Colony-Stimulating Factor
;
Granulocytes*
;
Humans
;
Hydroxyethyl Starch Derivatives*
;
Leukapheresis*
;
Neutropenia
;
Premedication
;
Tissue Donors
4.Two Families with Huntington's Disease.
Jeong Keon LIM ; Dang Do YI ; Chung kyu SUH ; Young Choon PARK ; Yeung Ju BYUN
Journal of the Korean Neurological Association 1989;7(1):172-177
Huntington's disease(HD) is a neurcdegenerative disorder caused by a highly penetrant autosomal dominant genetic defect. It is characterized by adult onset progressive chorea, psychological change, and dementia with relentless deterioration. Until now the reported cases are very rare in Korea, so we presented here two cases of definite HD.
Adult
;
Chorea
;
Dementia
;
Humans
;
Huntington Disease*
;
Korea
5.Platelet transfusion support for splenectomy in patients with chronic immune thrombocytopenic purpura.
Quehn PARK ; Jong Baeck LIM ; Keon Soo YI ; Mun Jeong KIM ; Hyun Ok KIM ; Kyung Soon SONG
Korean Journal of Blood Transfusion 1998;9(2):201-208
BACKGROUND: Splenectomy is often performed for the patients with refractory chronic immune thrombocytopenic purpura (ITP). Still, there are no generally accepted guidelines for the minimum level of platelet count and the average requirement of platelet transfusion so that the patients can safely undergo splenectomy. We evaluated the changes of platelet count and transfusion requirements around the splenectomy in patients with chronic ITP. METHODS: We reviewed the medical records of 25 patients with chronic ITP. We compared the platelet counts at admission, immediately pre-op and several post-op days. We also investigated the number of platelet concentrates transfused around splenectomy. We determined the effect of splenectomy according to Difino's classification. RESULTS: The median platelet counts of the patients was 18x109/L (7-238x109/L) on admission and recovered to 108x109/L (22-460x109/L) on preoperation day by platelet transfusion and immunosuppressive treatment. The platelet counts were rapidly recovered after splenectomy from the day of operation. Only 3 patients needed platelet transfusion after splenectomy. Thirteen among twenty five patients (52%) underwent operation without platelet transfusion support. Most transfusions were done before the surgery and 80% (12/15) of the patients required transfusion of more than 10 units of random donor platelet concentrate. Twenty one patients (84%) showed the complete remission after splenectomy. CONCLUSION: Splenectomy can lead to rapid remission even in most cases of refractory chronic ITP. Many cases can undergo the operation only with treatment modalities other than transfusion such as immunosuppressive agents and/or immunoglobulin. The minimum level of platelet counts for splenectomy may be safe over 50x109/L and about 10 units of platelet concentrate may be enough for preparation of splenectomy.
Blood Platelets*
;
Classification
;
Humans
;
Immunoglobulins
;
Immunosuppressive Agents
;
Medical Records
;
Platelet Count
;
Platelet Transfusion*
;
Purpura, Thrombocytopenic, Idiopathic*
;
Splenectomy*
;
Tissue Donors
6.High Dose Chemotherapy with Autologous Peripheral Blood Stem Cell Transplantation in Patients with Medulloblastoma/Primitive Neuroectodermal Tumor.
Ki Woong SUNG ; Keon Hee YOO ; Hong Hoe KOO ; Do Hoon LIM ; Hyung Jin SHIN ; Yoon Jeong KIM ; Seung Do AHN ; Young Shin RA ; Thad T GHIM
Korean Journal of Pediatric Hematology-Oncology 2001;8(2):264-272
PURPOSE: To improve survival and/or to avoid radiotherapy, high dose chemotherapy (HDCT) with autologous peripheral blood stem cell transplantation (PBSCT) was given to patients with recurrent or high risk medulloblastoma (MB)/primitive neuroectodermal tumor (PNET) as well as patients younger than 3 years of age. METHODS: Six patients (3 recurrent, 1 high risk, 2 younger than 3 years; 5 MBs and 1 PNET) received single or double HDCT and PBSCT with or without immunotherapy using interleukin-2. Chemotherapeutic regimen in the first HDCT included cyclophosphamide (1,500 mg/m2/ day for 4 days) and melphalan (60 mg/m2/day for 3 days). Chemotherapeutic regimen in the second HDCT included carboplatin (400 mg/m2/day for 3 days), thiotepa (250 mg/ m2/day for 3 days), and etoposide (200 mg/m2/day for 3 days). RESULTS: Nine HDCTs were applied in 6 patients. Three double HDCTs were rescued with peripheral blood stem cells collected during single round leukapheresis. Rapid hematologic recovery occurred in 4 patients. Engraft failure occurred in 1 patient and delayed granulocyte recovery and platelet engraft failure occurred in 1 patient. Three patients who had minimal disease before HDCT had event free survival for 7~18 months after HDCT. Tumor relapsed 8 and 12 months after single HDCT in 2 patients among 3 patients with recurrent MB/PNET. One patient with recurrent MB died due to engraft failure and sepsis. CONCLUSION: HDCT with autologous PBSCT is expected to improve survival of patients with poor prognosis MB/PNET including younger patients less than 3 years. Subsequent trials with larger number of patients and long-term follow-up are needed.
Blood Platelets
;
Carboplatin
;
Cyclophosphamide
;
Disease-Free Survival
;
Drug Therapy*
;
Etoposide
;
Follow-Up Studies
;
Granulocytes
;
Humans
;
Immunotherapy
;
Interleukin-2
;
Leukapheresis
;
Medulloblastoma
;
Melphalan
;
Neural Plate*
;
Neuroectodermal Tumors*
;
Neuroectodermal Tumors, Primitive
;
Peripheral Blood Stem Cell Transplantation*
;
Prognosis
;
Radiotherapy
;
Sepsis
;
Stem Cells
;
Thiotepa
7.A Case of Superimposed Viral Myocarditis in a Patient with Systemic Lupus Erythematosus.
Bong Geun SONG ; Byung Kwan LIM ; Min Hyung KIM ; Sung Chul SHIN ; Jae Hong JUNG ; Dong Hee KIM ; Jeong Hwan KIM ; Keon Woo PARK ; Eun Mi KOH ; Eun Seok JEON
Korean Circulation Journal 2003;33(12):1147-1150
Lupus myocarditis is usually treated using immunosuppressive agents, such as high-dose corticosteroids, azathioprine and cyclophosphamide. Viral myocarditis and enteroviruses have been identified as the most common causative agents of myocarditis in lupus patients. Although immunosuppressive therapy has an important role in the treatment of lupus myocarditis, it is not recommended in patients with infectious or post-infectious viral myocarditis, and supportive care is very important in these patients. A 25-year old female patient, with systemic lupus erythematosus, was admitted due to severe dyspnea, and diagnosed as having heart failure. She recovered 7 days after supportive care for heart failure, without Immuno-suppression. Her sera neutralized coxsackievirus B3 (CVB3) in neutralization test, with the horse anti-CVB3 antibody (Ab, ATCC V030-501-560) used as a positive control. The titers for the neutralizing Ab in her sera were 4 times higher than that of the standard control ATCC Ab.
Adrenal Cortex Hormones
;
Adult
;
Azathioprine
;
Cyclophosphamide
;
Dyspnea
;
Enterovirus
;
Female
;
Heart Failure
;
Horses
;
Humans
;
Immunosuppressive Agents
;
Lupus Erythematosus, Systemic*
;
Myocarditis*
;
Neutralization Tests
8.Extremely Low Frequency Magnetic Field Modulates the Level of Neurotransmitters.
Yoon Hee CHUNG ; Young Joo LEE ; Ho Sung LEE ; Su Jin CHUNG ; Cheol Hee LIM ; Keon Woong OH ; Uy Dong SOHN ; Eon Sub PARK ; Ji Hoon JEONG
The Korean Journal of Physiology and Pharmacology 2015;19(1):15-20
This study was aimed to observe that extremely low frequency magnetic field (ELF-MF) may be relevant to changes of major neurotransmitters in rat brain. After the exposure to ELF-MF (60 Hz, 2.0 mT) for 2 or 5 days, we measured the levels of biogenic amines and their metabolites, amino acid neurotransmitters and nitric oxide (NO) in the cortex, striatum, thalamus, cerebellum and hippocampus. The exposure of ELF-MF for 2 or 5 days produced significant differences in norepinephrine and vanillyl mandelic acid in the striatum, thalamus, cerebellum and hippocampus. Significant increases in the levels of serotonin and 5-hydroxyindoleacetic acid were also observed in the striatum, thalamus or hippocampus. ELF-MF significantly increased the concentration of dopamine in the thalamus. ELF-MF tended to increase the levels of amino acid neurotransmitters such as glutamine, glycine and gamma -aminobutyric acid in the striatum and thalamus, whereas it decreased the levels in the cortex, cerebellum and hippocampus. ELF-MF significantly increased NO concentration in the striatum, thalamus and hippocampus. The present study has demonstrated that exposure to ELF-MFs may evoke the changes in the levels of biogenic amines, amino acid and NO in the brain although the extent and property vary with the brain areas. However, the mechanisms remain further to be characterized.
Animals
;
Biogenic Amines
;
Brain
;
Cerebellum
;
Dopamine
;
Glutamine
;
Glycine
;
Hippocampus
;
Magnetic Fields*
;
Neurotransmitter Agents*
;
Nitric Oxide
;
Norepinephrine
;
Rats
;
Serotonin
;
Thalamus
9.Prevalence of Significant Coronary Arterial Disease in Adult Patients who Underwent Valvular Surgery in Korea.
Uhng Lim CHOI ; Sun Hwa LEE ; Jae Hyeong PARK ; Seok Woo SEONG ; Jun Hyung KIM ; Jae Hwan LEE ; Si Wan CHOI ; Jin Ok JEONG ; In Whan SEONG ; Kyoung Suk RHEE ; Jei Keon CHAE ; Won Ho KIM ; Jae Ki KO ; Myung Hoon NA ; Seung Pyung LIM ; Kyung Hwa KIM ; Jong Bum CHOI
Korean Journal of Medicine 2012;83(1):75-82
BACKGROUND/AIMS: The identification of significant coronary arterial disease (CAD) is important to reduce perioperative ischemic insult and the possibility of repeated open-chest surgery in patients scheduled to undergo valvular surgery. However, there are no published data on the incidence of significant CAD in these patients. Thus, we examined the prevalence of significant CAD in patients scheduled to undergo valvular surgery. METHODS: From January 2005 to June 2011, all consecutive adult patients diagnosed with significant valvular disease and scheduled for an elective open valvular operation were retrospectively investigated at Chungnam National University Hospital and Chonbuk National University Hospital. Patients who underwent emergent valvular operations due to acute aortic dissection or trauma and concomitant valvular operations at the time of coronary artery bypass graft (CABG) surgery were excluded. RESULTS: During the study period, a total of 431 patients (58 +/- 13 years old, 204 males) were included. The distributions of mitral (241 patients) and aortic valvular disease (230 patients) were similar. Coronary angiography was performed in 297 patients (68.9%). Of these, 36 (12.1%) showed significant CAD and 32 underwent concomitant CABG operations. Based on a multivariate analysis, the presence of CAD was significantly associated with old age (> or = 65 years old) [odds ratio (OR) = 3.081, 95% confidence interval (CI) = 1.372-6.921, p = 0.006], more cardiovascular risk factors (> or = 3) (OR = 3.002, 95% CI = 1.386-6.503, p = 0.005), and the presence of aortic stenosis (OR = 2.763, 95% CI = 1.269-6.013, p = 0.010). CONCLUSIONS: The incidence of significant CAD was 12.1% in adult patients who underwent valvular operations in Korea. CAD was more common in patients with old age, aortic stenosis, and multiple cardiovascular risk factors.
Adult
;
Aortic Valve Stenosis
;
Coronary Angiography
;
Coronary Artery Bypass
;
Coronary Artery Disease
;
Heart Valve Diseases
;
Humans
;
Incidence
;
Korea
;
Multivariate Analysis
;
Prevalence
;
Retrospective Studies
;
Risk Factors
;
Transplants
10.Reduced-dose craniospinal radiotherapy followed by high-dose chemotherapy and autologous stem cell rescue for children with newly diagnosed high-risk medulloblastoma or supratentorial primitive neuroectodermal tumor.
Sun Young KIM ; Ki Woong SUNG ; Jeong Ok HAH ; Keon Hee YOO ; Hong Hoe KOO ; Hyoung Jin KANG ; Kyung Duk PARK ; Hee Young SHIN ; Hyo Seop AHN ; Ho Joon IM ; Jong Jin SEO ; Yeon Jung LIM ; Young Ho LEE ; Hyung Jin SHIN ; Do Hoon LIM ; Byung Kyu CHO ; Young Shin RA ; Joong Uhn CHOI
Korean Journal of Hematology 2010;45(2):120-126
BACKGROUND: In this study, we investigated the effects of reduced-dose craniospinal radiotherapy (CSRT) followed by tandem high-dose chemotherapy (HDCT) with autologous stem cell rescue (ASCR) in children with a newly diagnosed high-risk medulloblastoma (MB) or supratentorial primitive neuroectodermal tumor (sPNET). METHODS: Between March 2005 and April 2007, patients older than 3 years with a newly diagnosed high-risk MB or sPNET were enrolled. The patients received two cycles of pre-RT chemotherapy consisting of cisplatin, etoposide, vincristine, and cyclophosphamide (cycle A), and carboplatin, etoposide, vincristine, and ifosphamide (cycle B), followed by CSRT with 23.4 Gy and local RT with 30.6 Gy. After four cycles of post-RT chemotherapy (cycles A, B, A, and B), tandem double HDCT with ASCR was performed. RESULTS: A total of 13 patients (MB=11, sPNET=2) were enrolled. Of these, one patient progressed, one patient died of septic shock after the second cycle of B, and one patient relapsed after the third cycle of B. The 3-year event-free survival (EFS) rate of the patients intended for HDCT was 76.9%, whereas the 3-year EFS rate of the patients who received HDCT was 100%. No treatment-related mortality occurred during HDCT. CONCLUSION: Although the follow-up period was short and the patient cohort was small in size, the results of this study are encouraging. The limited toxicity and favorable EFS rate observed in children treated with reduced-dose CSRT followed by HDCT and ASCR warrant further exploration in a larger study population.
Carboplatin
;
Child
;
Cisplatin
;
Cohort Studies
;
Cyclophosphamide
;
Disease-Free Survival
;
Etoposide
;
Follow-Up Studies
;
Humans
;
Medulloblastoma
;
Neuroectodermal Tumors, Primitive
;
Shock, Septic
;
Stem Cells
;
Vincristine